Fair Money & Economic Opportunity

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on mRNA medicines and vaccines.

The provided articles detail its financial performance, pipeline, and regulatory milestones related to drug development. There is no evidence in the articles pertaining to lending, insurance, deposit services, or any other activities related to financial services or economic opportunity for underserved populations. Consequently, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's core business model.

Fair Pay & Worker Respect

For fiscal year 2024, the CEO-to-median employee pay ratio was 14:1.

As of December 31, 2019, none of the company's 88 employees were represented by a labor union or covered by a collective bargaining agreement. Employee reviews on Glassdoor show an overall employee satisfaction rating of 3.4 out of 5 stars, based on 40 reviews. The company provides full health, dental, and vision insurance coverage for employees and dependents, and executive officers are eligible to participate in employee benefit plans on the same basis as other employees. On December 13, 2019, a former employee filed a complaint alleging sexual assault, seeking $30 million in damages, which the company intends to defend against. There is no quantitative data on living wage coverage, safety incident rate, pay equity ratio, voluntary employee turnover, or the share of the workforce on temporary or zero-hour contracts.

Fair Trade & Ethical Sourcing

The provided articles contain no specific, quantifiable data points to assess Arcturus Therapeutics Holdings Inc. (ARCT.US) against the Fair Trade & Ethical Sourcing value. While Article 2 states Arcturus' zero-tolerance policy for slavery and human trafficking and its prohibition of forced labor in its supply chain, these are policy statements and do not provide the necessary metrics such as the number of substantiated incidents or the percentage of supplier contracts with enforceable ethical clauses.

Information from articles referring to 'Arcturus Networks' (Articles 4 and 5) is not applicable to Arcturus Therapeutics Holdings Inc. Therefore, no KPIs can be scored based on the provided evidence.

Honest & Fair Business

Arcturus Therapeutics has a comprehensive Code of Business Conduct and Ethics, last edited December 6, 2021, which applies to all directors, officers, and employees.

This code includes a formal, confidential, and anonymous whistleblower hotline and secure web form for reporting suspicions of misconduct, including financial concerns. The SEC requires the company to provide this facility. Reports can be tracked with a 14 to 16-digit code and are delivered directly to the Audit Committee, which is responsible for enforcing the Code and evaluating alleged violations. The company identified material weaknesses in its internal control over financial reporting for the fiscal year ended December 31, 2023, specifically related to information technology general controls and controls over the review of costs incurred in satisfying collaboration arrangements. Arcturus' policies adhere to the U.S. Foreign Corrupt Practices Act (FCPA) and applicable foreign laws, prohibiting payments to government officials that could be construed as bribes. The policy sets a gift threshold of USD $100.00 and requires prior approval from the Chief Legal Officer for gifts exceeding this amount or for certain entertainment events related to government contracts. All political contributions must be approved by the CFO and CLO.

Kind to Animals

Arcturus Therapeutics conducts animal testing as part of its drug development process.

Preclinical studies for LUNAR®-OTC were conducted in a mouse model, and for LUNAR®-CF in animal models. The ARCT-021 vaccine was tested in primate macaque challenge models and humoral immunodeficient mice. While in vitro studies are mentioned for LUNAR®-CF, indicating some use of non-animal methods, traditional animal assays appear to dominate, consistent with a pharmaceutical company where non-animal methods are likely applied only where legally mandated. The company's policy prohibits discretionary testing, but legal mandates for drug development still necessitate animal testing. Arcturus does not have a public position on animal welfare legislation and is silent on industry standards, with no evidence of advocating for or against animal welfare policies.

Respect for Cultures & Communities

Arcturus Therapeutics has not evidenced formal partnerships with indigenous or local community groups; the partnerships mentioned are with other companies or foundations.

The company's business model as a global mRNA medicines and vaccines company does not inherently suggest a need for such partnerships, leading to a score of 0. There are no reported cultural appropriation incidents, cultural impact assessment protocols, or free, prior, and informed consent (FPIC) processes mentioned for Arcturus Therapeutics. Similarly, there is no evidence regarding community governance inclusion, cultural preservation investment, cultural site protection, or social license to operate. No information is provided on language inclusivity in Arcturus's products or communications, nor on cultural incident response frameworks or cultural sensitivity training completion for its employees. For these KPIs, a score of 0 is assigned as they are not applicable to the company's evidenced operations or no specific data is available.

Safe & Smart Tech

Arcturus Therapeutics Holdings Inc. has reported no material cybersecurity challenges that have affected or are reasonably likely to materially affect its operations or financial standing, as stated in its 10-K filings as of March 6, 2025, with an update on February 4, 2026.

The company implements and maintains various security measures, including incident detection and response, disaster recovery/business continuity policies, encryption of certain data, network security controls, access controls, physical security, asset management, and systems monitoring. It conducts annual mandated employee security training, penetration testing, threat and vulnerability assessments, and engages external experts for risk management evaluation and testing. The Audit Committee of the Board oversees cybersecurity risks, receiving briefings at least once per year. The company's privacy policy, last updated December 19, 2025, states that users can update personal information, preferences, or request deletion, and can set browser cookie preferences. It also acknowledges that email and Internet transmissions are not completely secure and assumes no responsibility for unencrypted transmissions. Arcturus is subject to and mentions compliance with various regulations, including HIPAA, GDPR, and CCPA. The company filed a federal lawsuit alleging misappropriation of trade secrets by a former employee and a consultant.

Zero Waste & Sustainable Products

Arcturus Therapeutics has designed its ATX lipid, a component of its LUNAR platform, to be rapidly biodegradable through engineered chemical structural components.

This design prevents the lipids from accumulating inside cells and causing toxicity. The company's operations involve hazardous and flammable materials, and it generally contracts with third parties for the disposal of these materials and wastes.